Humacyte(US:HUMA) Prnewswireยท2024-12-18 15:04Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 17, 2025 [2][4]. Group 1: Allegations Against Humacyte - The complaint alleges that Humacyte and its executives made false or misleading statements and failed to disclose significant issues regarding their manufacturing practices and FDA approval process [4]. - Specific allegations include non-compliance with good manufacturing practices at the Durham, North Carolina facility, leading to delays in the FDA's review of the Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) [4]. - The complaint suggests that these issues posed a substantial risk to the FDA approval of ATEV for vascular trauma, rendering the company's positive statements materially misleading [4]. Group 2: Stock Price Impact - Following a press release on August 9, 2024, regarding the FDA's need for additional time to review the BLA, Humacyte's stock price fell by $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [5]. - On October 17, 2024, the FDA released a Form 483 detailing violations at Humacyte's facility, resulting in a further decline of $0.95, or 16.35%, with the stock closing at $4.86 per share on the same day [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 between May 10, 2024, and October 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for January 17, 2025 [2][7].